Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
B and T Cell-Mediated Immunity 2.0
share announcement

B and T Cell-Mediated Immunity 2.0

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cellular/Molecular Immunology".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 3147

Special Issue Editors

Dr. Monica A. McArthur

E-Mail Website
Guest Editor
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Interests: pathogens; cellular immunology; T cell response; infectious diseases; vaccine development; vaccine immunology; Zika and other flaviviruses; enteric pathogens
Special Issues, Collections and Topics in MDPI journals
Dr. Franklin Toapanta

E-Mail Website
Guest Editor
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Interests: vaccine; immunology; microbiology; translational research; immune response; conjugated vaccines; therapeutic agents; enteric pathogens; respiratory pathogens; B cell response; T cell response; salmonella and shigella; influenza virus
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Generation of vigorous cell-mediated immune responses is critical to protection against many infectious diseases. T cells and B cells represent separate but interconnected arms of the adaptive immune response. As such, they are critical in providing long-lasting protection, thanks to the induction of immune memory, following vaccination or natural infection. This Special Issue focuses on T and B cell-mediated immunity as they relate to vaccination and protection against infectious diseases.  The goal is to enhance our knowledge of the important roles that T and B cells play to provide long-lasting protection. Understanding the contributions of T and B cells, as well as their interactions, following vaccination and/or natural infection could provide critical insights that will help further vaccine development.

Dr. Monica A. McArthur
Dr. Franklin Toapanta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Dr. Monica A. McArthur
Dr. Franklin Toapanta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Vaccine immunology
  • T-cell mediated immunity
  • B-cell mediated immunity
  • cellular immunology
  • infectious diseases
  • clinical trials
  • translational research
  • animal models

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

20 pages, 674 KiB  
Review
Current Vaccine Platforms in Enhancing T-Cell Response
by Takehiro Ura, Masaki Takeuchi, Tatsukata Kawagoe, Nobuhisa Mizuki, Kenji Okuda and Masaru Shimada
Vaccines 2022, 10(8), 1367; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10081367 - 21 Aug 2022
Cited by 9 | Viewed by 2438
Abstract
The induction of T cell-mediated immunity is crucial in vaccine development. The most effective vaccine is likely to employ both cellular and humoral immune responses. The efficacy of a vaccine depends on T cells activated by antigen-presenting cells. T cells also play a [...] Read more.
The induction of T cell-mediated immunity is crucial in vaccine development. The most effective vaccine is likely to employ both cellular and humoral immune responses. The efficacy of a vaccine depends on T cells activated by antigen-presenting cells. T cells also play a critical role in the duration and cross-reactivity of vaccines. Moreover, pre-existing T-cell immunity is associated with a decreased severity of infectious diseases. Many technical and delivery platforms have been designed to induce T cell-mediated vaccine immunity. The immunogenicity of vaccines is enhanced by controlling the kinetics and targeted delivery. Viral vectors are attractive tools that enable the intracellular expression of foreign antigens and induce robust immunity. However, it is necessary to select an appropriate viral vector considering the existing anti-vector immunity that impairs vaccine efficacy. mRNA vaccines have the advantage of rapid and low-cost manufacturing and have been approved for clinical use as COVID-19 vaccines for the first time. mRNA modification and nanomaterial encapsulation can help address mRNA instability and translation efficacy. This review summarizes the T cell responses of vaccines against various infectious diseases based on vaccine technologies and delivery platforms and discusses the future directions of these cutting-edge platforms. Full article
(This article belongs to the Special Issue B and T Cell-Mediated Immunity 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop